Aktieselskabet Schouw & Co.
6.11.2026 08:02:00 CET | Globenewswire | Press release
Schouw & Co. raises its full-year 2026 guidance on revenue and EBITDA
Schouw & Co. raises its full-year 2026 guidance on revenue and EBITDA
Schouw & Co. will today be releasing its interim report for the third quarter of 2026. The interim report contains inside information, as the guidance for full-year revenue and EBITDA differs from the guidance expressed in the company’s interim report for the second quarter of 2026 released on 14 August 2026 and in connection with closing of the acquisition of Spectre on 1 September 2026.
Schouw & Co. increases its guidance for FY 2026 consolidated revenue to the range of DKK 36.2-38.1 from previously DKK 35.1-37.6 billion. At the same time, the guidance for FY 2026 consolidated EBITDA is raised to the range of DKK 3,375-3,525 million from previously DKK 3,150-3,350 million.
The upgraded guidance is based on the Board of Directors’ and the Executive Management’s assessment of the outlook for the Group’s businesses for the rest of the year, including the information on BioMar’s guidance in company announcement no. 66 of 2 November 2026.
The company’s full interim report for the third quarter of 2026 will be released immediately following this message.
Aktieselskabet Schouw & Co.
Jørgen Wisborg, Chairman of the Board of Directors
Jens Bjerg Sørensen, President & CEO
Please direct any questions to President Jens Bjerg Sørensen, telephone no. +45 86 11 22 22.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sveriges Riksbank6.11.2026 10:05:00 CET | Press release
RESULT OF RIKSBANK AUCTIONS GOVERNMENT BONDS
Chery Auto6.11.2026 09:49:48 CET | Press release
LEPAS L6 EV Impresses Global Elegant Driving Ambassadors on First-Ever LEPAS Global Journey of Elegant Driving
Image Soft Oy6.11.2026 09:39:28 CET | Press release
Elering Partners with Image Soft to Safeguard Baltic Sea Subsea Energy Infrastructure with Advanced UNWAS™ Technology
Ultragenyx Pharmaceutical Inc.6.11.2026 09:30:00 CET | Press release
Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
LUYUAN Group6.11.2026 09:00:00 CET | Press release
LUYUAN and LYVA Make European Debut at EICMA 2026 with Five Concepts and Global Smart Mobility Strategy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom